Azolopyrimidine for the treatment of cancer-related disorders
US-11072597-B2 · Jul 27, 2021 · US
Azolopyrimidine for the treatment of cancer-related disorders
US12195447B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12195447-B2 |
| Application number | US-202117507921-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 22, 2021 |
| Priority date | Jan 20, 2017 |
| Publication date | Jan 14, 2025 |
| Grant date | Jan 14, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compound that is an inhibitor of at least one of the A 2A and A 2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A 2A receptor and/or the adenosine A 2B receptor.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12195447B2 cover?
- Compound that is an inhibitor of at least one of the A 2A and A 2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part…
- Who is the assignee on this patent?
- Arcus Biosciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).